Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRWDNASDAQ:RIGLNASDAQ:VSTMNASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$0.60-1.3%$0.85$0.53▼$7.11$97.43M0.372.58 million shs1.74 million shsRIGLRigel Pharmaceuticals$20.54+0.7%$18.41$7.48▼$29.82$367.09M1.34218,479 shs136,037 shsVSTMVerastem$6.17+4.6%$6.58$2.10▼$9.10$339.04M0.851.13 million shs1.96 million shsZBIOZenas Biopharma$9.55+0.3%$9.39$5.83▼$26.25$399.52MN/A181,818 shs102,829 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals-1.63%-2.04%-34.58%-60.40%-91.04%RIGLRigel Pharmaceuticals+1.19%+3.92%+5.32%+0.49%+107.41%VSTMVerastem-1.99%-30.75%-20.59%-1.67%+49.75%ZBIOZenas Biopharma-5.37%-9.85%-20.13%+951,999,900.00%+951,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRWDIronwood Pharmaceuticals4.4517 of 5 stars4.13.00.03.42.00.81.9RIGLRigel Pharmaceuticals2.7831 of 5 stars3.21.00.00.03.41.71.9VSTMVerastem3.0605 of 5 stars4.50.00.00.03.22.50.6ZBIOZenas BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRWDIronwood Pharmaceuticals 2.13Hold$4.78694.44% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4077.22% UpsideVSTMVerastem 3.00Buy$13.63120.83% UpsideZBIOZenas Biopharma 3.00Buy$36.67283.94% UpsideCurrent Analyst Ratings BreakdownLatest IRWD, ZBIO, VSTM, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ZBIOZenas BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ZBIOZenas BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.004/16/2025IRWDIronwood PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025IRWDIronwood PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.004/15/2025IRWDIronwood PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $0.704/14/2025IRWDIronwood PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.004/14/2025IRWDIronwood PharmaceuticalsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRWDIronwood Pharmaceuticals$317.68M0.31N/AN/A($2.21) per share-0.27RIGLRigel Pharmaceuticals$203.08M1.81N/AN/A($1.64) per share-12.52VSTMVerastem$10M33.90N/AN/A$2.27 per share2.72ZBIOZenas Biopharma$15M26.63N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRWDIronwood Pharmaceuticals-$1.00B-$0.20N/A2.41N/A-0.65%-0.96%0.74%8/14/2025 (Estimated)RIGLRigel Pharmaceuticals-$25.09M$2.07146.7219.56N/A2.46%-14.80%3.03%8/5/2025 (Estimated)VSTMVerastem-$87.37M-$3.20N/AN/AN/AN/A-332.73%-73.97%8/14/2025 (Estimated)ZBIOZenas BiopharmaN/A-$3.55N/A∞N/AN/AN/AN/AN/ALatest IRWD, ZBIO, VSTM, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ZBIOZenas Biopharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 million3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A3/4/2025Q4 2024RIGLRigel Pharmaceuticals$0.30$0.80+$0.50$0.80$57.59 million$57.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AZBIOZenas Biopharma$0.050.50%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRWDIronwood PharmaceuticalsN/A3.623.62RIGLRigel PharmaceuticalsN/A1.961.87VSTMVerastem2.773.233.23ZBIOZenas BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRWDIronwood PharmaceuticalsN/ARIGLRigel Pharmaceuticals66.23%VSTMVerastem88.37%ZBIOZenas BiopharmaN/AInsider OwnershipCompanyInsider OwnershipIRWDIronwood Pharmaceuticals12.90%RIGLRigel Pharmaceuticals9.48%VSTMVerastem2.10%ZBIOZenas BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRWDIronwood Pharmaceuticals220161.82 million139.38 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.02 millionOptionableVSTMVerastem5054.95 million43.53 millionOptionableZBIOZenas BiopharmaN/A41.83 millionN/AN/AIRWD, ZBIO, VSTM, and RIGL HeadlinesRecent News About These CompaniesInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 4 at 4:30 PM | accessnewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc. (ZBIO) ShareholdersJune 4 at 1:00 PM | globenewswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 4 at 12:30 PM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 4 at 11:50 AM | accessnewswire.comLost Money on Zenas BioPharma, Inc. (ZBIO)? Contact Levi & Korsinsky to Join Class Action Before June 16, 2025June 4 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 4 at 9:40 AM | prnewswire.comClass Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Recover Losses - Contact Levi & Korsinsky Before June 16, 2025June 4 at 7:25 AM | accessnewswire.comZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!June 4 at 7:00 AM | accessnewswire.comJoin Class Action to Recover Losses From Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025June 3 at 2:00 PM | accessnewswire.comLevi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025June 3 at 11:55 AM | accessnewswire.comZBIO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIOJune 3 at 11:30 AM | accessnewswire.comClass Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Recover Losses - Contact Levi & Korsinsky Before June 16, 2025June 3 at 10:55 AM | accessnewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 3 at 9:30 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit And Upcoming Deadlines - ZBIOJune 3 at 9:00 AM | accessnewswire.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 3 at 7:30 AM | accessnewswire.comZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!June 3 at 7:00 AM | accessnewswire.comZenas Biopharma Inc (NASDAQ:ZBIO) Shares Sold by Wellington Management Group LLPJune 3 at 4:27 AM | marketbeat.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure ...June 2 at 10:55 PM | eagletribune.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 2 at 10:00 PM | accessnewswire.comSecurities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents ShareholdersJune 2 at 1:45 PM | accessnewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 2 at 1:26 PM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRWD, ZBIO, VSTM, and RIGL Company DescriptionsIronwood Pharmaceuticals NASDAQ:IRWD$0.60 -0.01 (-1.28%) As of 04:00 PM EasternIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$20.54 +0.15 (+0.74%) As of 04:00 PM EasternRigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$6.17 +0.27 (+4.58%) As of 04:00 PM EasternVerastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Zenas Biopharma NASDAQ:ZBIO$9.55 +0.03 (+0.32%) As of 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
